GLMD News Alert Galmed Pharmaceuticals Ltd. (GLMD) 8.79 09/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Galmed Pharmaceuticals Ltd. (GLMD) 8.79 $GLMD

Galmed's Aramchol Gets Fast-Track Designation in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:45PM CDT
Galmed Pharmaceuticals Ltd. (GLMD) announced that the FDA has granted fast track status to aramchol for the treatment of non-alcoholic steato-hepatitis.

Galmed Pharmaceuticals acquires US FDA's Fast Track Designation for Aramchol for NASH
M2 - Wed Sep 24, 6:24AM CDT
Biopharmaceutical company Galmed Pharmaceuticals (NasdaqCM :GLMD) reported on Tuesday the receipt of the US Food and Drug Administration's Fast Track Designation for aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.

Market Maker Surveillance Report. RITT, JRJC, UQM, GLMD, SINO, ECTE, Winning Stocks With Lowest Price Friction For Tuesday, September 23rd 2014
M2 - Wed Sep 24, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4582 companies with "abnormal" market making, 1424 companies with positive Friction Factors and 3854 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Rit Technologies Ltd (NASDAQ:RITT), China Finance Online Co Ltd (NASDAQ:JRJC), UQM Technologies Inc (NYSE:UQM), GOLD MEDAL RES LTD (NASDAQ:GLMD), Sino-Global Shipping America Ltd (NASDAQ:SINO), Echo Therapeutics Inc (NASDAQ:ECTE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today
at The Street - Tue Sep 23, 2:50PM CDT
Shares of Galmed Pharmaceuticals (GLMD) soared Tuesday after the company announced the FDA had given Fast Track Designation to its drug candidate aramchol.

Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH
PR Newswire - Tue Sep 23, 9:47AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that the U.S. Food and Drug Administration, or the FDA, approved its request for Fast Track Designation of its product candidate, aramchol, for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.

Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events
PR Newswire - Tue Sep 02, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it successfully completed two six-month chronic toxicology studies of its drug candidate, aramchol. These studies were performed in compliance with the European Medicines Agency's ICH M3 (R2) guidelines by WIL Research, a global contract research organization, at its facility in Holland. The studies are required in advance of the commencement of human clinical trials and marketing authorization for pharmaceuticals in Europe and support Galmed's planned Phase IIb clinical trial of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH, in patients who also suffer from obesity and insulin resistance, which Galmed intends to initiate in the European Union, Israel and Latin America later this year. Galmed is continuing these two toxicology studies for an additional three months to satisfy an initial requirement of the U.S. Food and Drug Administration to complete nine-month pre-clinical toxicology studies of aramchol prior to conducting clinical trials in the United States.

Galmed Pharmaceuticals Reports First Half 2014 Financial Results
PR Newswire - Fri Jul 25, 7:00AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
PR Newswire - Tue Jul 22, 8:20AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that the U.S. Food and Drug Administration, or the FDA, cleared Galmed's Investigational New Drug, or IND, application. Such clearance will permit Galmed to conduct clinical trials of its product candidate, aramchol, in the United States for the treatment of fatty liver disorders. Galmed is initially developing aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. According to scientific literature, NASH is a chronic disease that affects approxiately12% of the population in United States and in certain European Union nations and its prevalence is expected to increase in parallel with increased rates of obesity and diabetes. There are currently no approved drugs to treat NASH.

Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
PR Newswire - Mon Jul 21, 8:08AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it will host a conference call and webcast on Friday, July 25, 2014 to discuss results for the period ended June 30, 2014 and to provide an update on current developments with respect to its clinical program for aramchol.

Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal
PR Newswire - Tue Jul 08, 9:33AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed" today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal.

Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs
ACCESSWIRE - Thu Jun 26, 8:41AM CDT
WHITEFISH, MT / June 26, 2014 / Those following the developments of Intercept Pharmaceuticals (NASDAQ: ICPT), Galectin Therapeutics (NASDAQ: GALT) and Galmed Pharmaceuticals (NASDAQ: GLMD) are keenly aware of the tendency of fatty liver disease drug developers to move in unity upon news of clinical research. The lack of viable treatments, increasing diagnosis rates and the economic burden associated with fatty livers has put a spotlight on the limited number of companies pursuing the indication, keeping investors on the lookout for news with market moving potential.

Leading Companies Being Defined in the Hunt for a NASH Treatment
ACCESSWIRE - Thu Mar 27, 9:32AM CDT
March 27, 2014 / The race to develop a treatment for Non-Alcoholic Steatohepatitis (NASH) is getting a lot of airtime lately, pointing to the severity of the disease, poor prognosis and desperate need for a treatment. The space has only a handful of competitors, with most seeing rising valuations due to the tremendous peak sales that analysts are projecting for products that make it to market. What is particularly unique to this disease is not only the lack of any approved treatments, but also the influx of attention and growing broad body of research by companies like Intercept Pharmaceuticals (NASDAQ: ICPT), Galmed Pharmaceuticals (NASDAQ: GLMD) and Galectin Therapeutics (NASDAQ: GALT) that shows treatments are on the horizon, which gives these equities considerable upside.

Galmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Tue Mar 18, 10:40AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" today announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters' option to purchase additional ordinary shares to cover over-allotments. The aggregate gross proceeds from the sale of the shares were approximately $44.1 million, before deducting underwriting discounts, commissions and other estimated offering expenses. The net proceeds from the sale of the shares, after deducting underwriting discounts, commissions and other estimated offering expenses were approximately $39.7 million. The ordinary shares issued in the offering are listed on the NASDAQ Capital Market under the trading symbol "GLMD."

Galmed Pharmaceuticals Announces Pricing of Initial Public Offering
PR Newswire - Wed Mar 12, 7:07PM CDT
Galmed Pharmaceuticals Ltd. ("Galmed" today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions. Galmed has granted the underwriters an option for a period of 45 days to purchase, at the public offering price less the underwriting discount, up to 425,610 additional ordinary shares to cover over-allotments. The shares to be issued in the offering have been approved for listing on the NASDAQ Capital Market and are expected to begin trading under the ticker symbol "GLMD" on March 13, 2014.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 141

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 0

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 154

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 114

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 24

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 0

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 6

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Share Buybacks and Voting Rights Dynamics

Updated Category News Views 130

Overview of Share Buybacks In recent financial news, Octopus AIM VCT plc has engaged in a strategic move by purchasing its own shares. This action is often a signal of confidence in the company's future and an investment in its own value. Details of the Transaction The company has recently announced the acquisition of 590,908 ordinary shares at a price of 47.27p each....

Continue Reading
Kojamo's Financial Report Highlights: Growth and Outlook

Updated Category News Views 186

Overview of Kojamo plc's Financial Performance Kojamo plc has recently published its financial report, highlighting significant changes and developments in their occupancy rates and revenues for the first half of the fiscal year. This report is particularly important for investors and stakeholders keen on understanding the company's financial health. Financial Highlights...

Continue Reading
Silicom Ltd. Partners with U.S. Firm for Edge Networking Growth

Updated Category News Views 167

Silicom Ltd. Partners with Provider for Edge Networking Solutions - $1 million annual run rate with potential for a significant multi-million-dollar scale-up - Silicom Ltd. (NASDAQ: SILC), a recognized leader in networking and data infrastructure solutions, has announced an exciting collaboration with a U.S.-based provider specializing in Edge networking solutions...

Continue Reading
Understanding the Ongoing Securities Case Against Five Below, Inc.

Updated Category News Views 120

Overview of the Class Action Lawsuit Against Five Below, Inc. As an investor, it's essential to stay informed about your rights, especially with ongoing legal matters. Currently, a notable class action lawsuit is underway involving Five Below, Inc. (NASDAQ: FIVE), which is particularly relevant for its shareholders. Class Period Details The allegations pertain to the time...

Continue Reading
Worthington Enterprises to Boost Portfolio with LSI Group Buyout

Updated Category News Views 169

Worthington Enterprises Expands Its Portfolio with Major Acquisition Worthington Enterprises Inc. (NYSE: WOR), renowned for its innovative designs and manufacturing prowess, has officially announced its intent to acquire LSI Group, LLC. This major acquisition positions Worthington Enterprises to enhance its offerings and market presence in the metal roofing sector....

Continue Reading